{"id":45033,"date":"2023-11-10T10:32:11","date_gmt":"2023-11-10T08:32:11","guid":{"rendered":"https:\/\/www.ipsen.com\/?p=45033"},"modified":"2024-05-20T12:13:38","modified_gmt":"2024-05-20T10:13:38","slug":"examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon","status":"publish","type":"post","link":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/","title":{"rendered":"Examen de la l\u00e9gislation pharmaceutique europ\u00e9enne : EFPIA publie le rapport Dolon"},"content":{"rendered":"\n<p>La F\u00e9d\u00e9ration europ\u00e9enne des associations et industries pharmaceutiques (EFPIA) a demand\u00e9 \u00e0 Dolon d&#8217;\u00e9laborer un rapport pour \u00e9valuer l&#8217;impact de la proposition de l\u00e9gislation pharmaceutique d\u00e9velopp\u00e9e la Commission europ\u00e9enne. Le rapport Dolon, publi\u00e9 le 6 novembre, conclut que la l\u00e9gislation telle que propos\u00e9e en l\u2019\u00e9tat par la Commission pourrait avoir un impact n\u00e9gatif sur la recherche et le d\u00e9veloppement dans l&#8217;industrie pharmaceutique en Europe, et potentiellement sur la vie des patients dans le monde entier.\u00a0 Certaines de ces possibles cons\u00e9quences sont illustr\u00e9es ci-dessous. \u00a0<\/p>\n\n\n\n<figure class=\"wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"509\" height=\"504\" data-id=\"45027\" src=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Image1-1.png\" alt=\"\" class=\"wp-image-45027\" srcset=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Image1-1.png 509w, https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Image1-1.png?resize=150,150 150w, https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Image1-1.png?resize=300,297 300w\" sizes=\"auto, (max-width: 509px) 100vw, 509px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"331\" height=\"330\" data-id=\"45034\" src=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Image2-2.png\" alt=\"\" class=\"wp-image-45034\" srcset=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Image2-2.png 331w, https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Image2-2.png?resize=150,150 150w, https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Image2-2.png?resize=300,300 300w\" sizes=\"auto, (max-width: 331px) 100vw, 331px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"337\" height=\"342\" data-id=\"45024\" src=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Image3-1.png\" alt=\"\" class=\"wp-image-45024\" srcset=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Image3-1.png 337w, https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Image3-1.png?resize=148,150 148w, https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Image3-1.png?resize=296,300 296w\" sizes=\"auto, (max-width: 337px) 100vw, 337px\" \/><\/figure>\n<\/figure>\n\n\n\n<p>Pour en savoir plus sur l&#8217;impact potentiel la proposition de la Commission europ\u00e9enne: le communiqu\u00e9 de presse de l&#8217;EFPIA est accessible <a href=\"https:\/\/www.efpia.eu\/news-events\/the-efpia-view\/statements-press-releases\/germany-belgium-and-france-among-those-hit-hardest-as-commission-s-pharma-legislation-proposals-risk-europe-losing-a-third-of-its-share-of-global-rd-by-2040\/\"><strong>ici<\/strong><\/a> et le rapport complet <strong><a href=\"https:\/\/www.efpia.eu\/media\/msadqxbf\/revision-of-the-general-pharmaceutical-legislation-gpl-impact-assessment.pdf\">ici<\/a><\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La F\u00e9d\u00e9ration europ\u00e9enne des associations et industries pharmaceutiques (EFPIA) a demand\u00e9 \u00e0 Dolon d&#8217;\u00e9laborer un rapport pour \u00e9valuer l&#8217;impact de<\/p>\n","protected":false},"author":11,"featured_media":45030,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[121],"tags":[],"class_list":["post-45033","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Examen de la l\u00e9gislation pharmaceutique europ\u00e9enne : EFPIA publie le rapport Dolon<\/title>\n<meta name=\"description\" content=\"D\u00e9couvrez les conclusions du rapport Dolon publi\u00e9 par EFPIA \u00e9valuant la proposition de l\u00e9gislation pharmaceutique europ\u00e9enne et son impact sur l\u2019industrie.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Examen de la l\u00e9gislation pharmaceutique europ\u00e9enne : EFPIA publie le rapport Dolon\" \/>\n<meta property=\"og:description\" content=\"D\u00e9couvrez les conclusions du rapport Dolon publi\u00e9 par EFPIA \u00e9valuant la proposition de l\u00e9gislation pharmaceutique europ\u00e9enne et son impact sur l\u2019industrie.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-10T08:32:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-20T10:13:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1082\" \/>\n\t<meta property=\"og:image:height\" content=\"620\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"heloisedetouchet\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"heloisedetouchet\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/\"},\"author\":{\"name\":\"heloisedetouchet\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/2c275168b31beee81688f3c041877318\"},\"headline\":\"Examen de la l\u00e9gislation pharmaceutique europ\u00e9enne : EFPIA publie le rapport Dolon\",\"datePublished\":\"2023-11-10T08:32:11+00:00\",\"dateModified\":\"2024-05-20T10:13:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/\"},\"wordCount\":141,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg\",\"articleSection\":[\"General\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/\",\"name\":\"Examen de la l\u00e9gislation pharmaceutique europ\u00e9enne : EFPIA publie le rapport Dolon\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg\",\"datePublished\":\"2023-11-10T08:32:11+00:00\",\"dateModified\":\"2024-05-20T10:13:38+00:00\",\"description\":\"D\u00e9couvrez les conclusions du rapport Dolon publi\u00e9 par EFPIA \u00e9valuant la proposition de l\u00e9gislation pharmaceutique europ\u00e9enne et son impact sur l\u2019industrie.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg\",\"width\":1082,\"height\":620},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Examen de la l\u00e9gislation pharmaceutique europ\u00e9enne : EFPIA publie le rapport Dolon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/2c275168b31beee81688f3c041877318\",\"name\":\"heloisedetouchet\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a294050dc7df14814ce352dcd30bd2b11c1bf6f269c4edf2111b59216f02bb15?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a294050dc7df14814ce352dcd30bd2b11c1bf6f269c4edf2111b59216f02bb15?s=96&d=mm&r=g\",\"caption\":\"heloisedetouchet\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Examen de la l\u00e9gislation pharmaceutique europ\u00e9enne : EFPIA publie le rapport Dolon","description":"D\u00e9couvrez les conclusions du rapport Dolon publi\u00e9 par EFPIA \u00e9valuant la proposition de l\u00e9gislation pharmaceutique europ\u00e9enne et son impact sur l\u2019industrie.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/","og_locale":"fr_FR","og_type":"article","og_title":"Examen de la l\u00e9gislation pharmaceutique europ\u00e9enne : EFPIA publie le rapport Dolon","og_description":"D\u00e9couvrez les conclusions du rapport Dolon publi\u00e9 par EFPIA \u00e9valuant la proposition de l\u00e9gislation pharmaceutique europ\u00e9enne et son impact sur l\u2019industrie.","og_url":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/","og_site_name":"Global","article_published_time":"2023-11-10T08:32:11+00:00","article_modified_time":"2024-05-20T10:13:38+00:00","og_image":[{"width":1082,"height":620,"url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg","type":"image\/jpeg"}],"author":"heloisedetouchet","twitter_card":"summary_large_image","twitter_creator":"@ipsengroup","twitter_site":"@ipsengroup","twitter_misc":{"Written by":"heloisedetouchet","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/"},"author":{"name":"heloisedetouchet","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/2c275168b31beee81688f3c041877318"},"headline":"Examen de la l\u00e9gislation pharmaceutique europ\u00e9enne : EFPIA publie le rapport Dolon","datePublished":"2023-11-10T08:32:11+00:00","dateModified":"2024-05-20T10:13:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/"},"wordCount":141,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg","articleSection":["General"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/","url":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/","name":"Examen de la l\u00e9gislation pharmaceutique europ\u00e9enne : EFPIA publie le rapport Dolon","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg","datePublished":"2023-11-10T08:32:11+00:00","dateModified":"2024-05-20T10:13:38+00:00","description":"D\u00e9couvrez les conclusions du rapport Dolon publi\u00e9 par EFPIA \u00e9valuant la proposition de l\u00e9gislation pharmaceutique europ\u00e9enne et son impact sur l\u2019industrie.","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#primaryimage","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg","width":1082,"height":620},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/general-fr\/examen-de-la-legislation-pharmaceutique-europeenne-efpia-publie-le-rapport-dolon\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Examen de la l\u00e9gislation pharmaceutique europ\u00e9enne : EFPIA publie le rapport Dolon"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/2c275168b31beee81688f3c041877318","name":"heloisedetouchet","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a294050dc7df14814ce352dcd30bd2b11c1bf6f269c4edf2111b59216f02bb15?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a294050dc7df14814ce352dcd30bd2b11c1bf6f269c4edf2111b59216f02bb15?s=96&d=mm&r=g","caption":"heloisedetouchet"}}]}},"jetpack_featured_media_url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/11\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/45033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/comments?post=45033"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/45033\/revisions"}],"predecessor-version":[{"id":45039,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/45033\/revisions\/45039"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media\/45030"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=45033"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=45033"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=45033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}